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The emergence, spread, and expansion of antibiotic resistance and increasing
restrictions on the use of antibiotics in animal agriculture have created a need
for efficacious alternatives that remains unmet. Prioritizing research needs in the
development of alternatives is key to ensuring that scarce research resources are
dedicated to the most promising approaches. However, frameworks to enable a
consistent, systematic, and transparent evaluation of antibiotic alternative candidates
are lacking. Here, we present such an evaluation framework.
Keywords: antibiotic resistance, animal agriculture, antibiotic alternatives, research prioritization, evaluation
framework
INTRODUCTION
Traditional antimicrobial drugs, or antibiotics1, are critical tools to promote human and animal
health, yet their efficacy is increasingly threatened by antibiotic resistance2. Any exposure to
antibiotics can select for resistant bacteria; therefore, their use in all settings must be carefully
managed (1). In response to this global public health challenge and growing consumer concerns
about food production practices, increasing numbers of food companies are voluntarily limiting
the use of antibiotics in their supply chains (2).
For the purpose of this study, and consistent with other established definitions [see for instance
(3, 4)], alternatives to antibiotics were broadly defined as any substance that can prevent the
need for or be substituted for antimicrobial drugs. This includes a wide variety of substances
including microbial-derived products (e.g., probiotics, bacteriophages, and bacteriophage-derived
products), phytochemicals (e.g., essential oils), immune-derived products (e.g., antimicrobial
peptides, immunomodulators), vaccines, enzymes, metals, minerals, and innovative animal drugs.
1Note that we use the term antibiotic in this paper to be consistent with common industry language and to avoid confusion
with those alternatives that are antimicrobials; however, it is important to note that the terms often are used interchangeably,
though technically antibiotics are a subset of antimicrobials.
2https://www.cdc.gov/antibiotic-use/stewardship-report/hospital.html
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While many of the currently available alternatives enhance
animal health and thus reduce the need for antibiotics, they
cannot fully replace them. The need for effective alternatives
that can more predictably prevent, control or treat disease has
remained largely unmet (5)3.
Public and private sector funding for research on antibiotic
alternatives in animal agriculture is scarce (6). Prioritization
is needed to ensure limited resources are dedicated to the
most promising and impactful research areas and potential
candidates (6). Ideally, the success or failure of an antibiotic
alternative would be predictable early during the research and
development (R&D) process. However, products may fail at
many stages, including after they are fully commercialized.
A framework to evaluate antibiotic alternatives early in R&D
and enable the consistent and transparent prioritization of
investments is sorely needed. This manuscript summarizes
the outcomes of an expert workshop organized to address
this need.
WORKSHOP GOALS AND OBJECTIVES
A pre-workshop survey of over 40 experts in animal agriculture
identified antibiotic alternatives as the top research priority
related to antibiotic stewardship, prompting its selection as
the workshop topic (details available upon request). For
the purposes of the workshop, antibiotic alternatives were
defined broadly as animal feed additives (e.g., phytochemicals,
pre- and pro-biotics, organic acids) as well as animal drugs
(e.g., immune modulators) and veterinary biologics (e.g.,
novel vaccines, antibodies) that prevent, control, or treat
infectious diseases. In contrast, management practices such
as nutritional or backgrounding strategies, improvements in
housing, or more stringent biosecurity were excluded from
the discussion.
For the workshop, a panel of 23 subject matter experts
from academia, industry, governmental, and non-governmental
organizations convened for a 1 day in-person meeting in
December 2018. The goal was to identify strategic priorities
for funding research and development on antibiotic alternatives
in animal agriculture. The workshop explored factors critical
to the success or failure of new antibiotic alternatives and
identified associated data gaps and research needs that,
if addressed, could help grow the pipeline of safe and
effective product candidates. The workshop consisted of two
facilitated discussions to reach consensus on key factors
important in the evaluation of research approaches and funding
decision-making for antibiotic alternatives. This manuscript
highlights key themes that emerged during the workshop and,
in certain instances, develops them further. All workshop




PREDICTING SUCCESS OR FAILURE OF
AN ANTIBIOTIC ALTERNATIVE
Successful antibiotic alternatives solve a substantial real-world
infectious disease problem and provide an economic and animal
health benefit. An entity or entities must be willing to invest in
scientific research to bring the product to market, and someone
must be willing to purchase and use it. However, that alone
is not sufficient for successful adoption. The ability of farmers
and veterinarians to use the product relies on additional factors
such as the logistics of delivery and storage and whether the
product aligns with their own and their customers’ values
and expectations. Ultimately, many factors influence whether
an alternative is successful. Table 1 provides a framework for
evaluating the potential success of an antibiotic alternative
candidate, starting with an assessment of overall economic
viability, followed by a more in-depth assessment of specific risks
to product success.
Assessing the Economic Viability of the
Project
Profitability is foundational to the success of an antibiotic
alternative; farmers and veterinarians cannot adopt economically
unsustainable products. Similarly, without a viable business
model, investors and pharmaceutical companies are unlikely
to provide sufficient funding to bring the concept to market.
Economic viability is therefore the first framework criterion,
although it can be difficult to predict. For instance, in 2018, <2
years after gaining FDA approval, the animal pharmaceutical
company that developed Imrestor R©, an antibiotic alternative
addressing mastitis in dairy cattle, decided to suspend its
commercialization (7, 8).
To determine economic viability, animal health companies
and investors evaluate the potential product’s expected revenue
and probability of success, compared to anticipated costs and
risks (9). These evaluations usually take a global perspective,
and factor in relevant national and regional policies, such as
current or likely future antibiotic use restrictions and the broader
regulatory landscape.
Expected Project Costs
The initial discovery and development of a new animal
health product typically incurs substantial costs, as outlined in
Table 1. Product manufacturing, service, distribution, disposal
and extensions to new species or indications can constitute
substantial additional costs which may be challenging to
predict during initial development stages (9). Uncertainty in
the predicted project cost and associated risks, including the
probability of regulatory success or public acceptance, will also
discourage investment.
Expected Product Revenue
To predict product revenue, investors analyze both the market
and the product’s expected performance in it. The predicted
market size for an antibiotic alternative ultimately depends on
the number of farms and animals affected by the disease and
on how likely the producer or veterinarian is to proactively take
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TABLE 1 | Framework for evaluating the success of an antibiotic alternative.
Framework Check-list items
1. Overall economic viability
a. Expected project costs - Product development
• Research and Development (R&D) costs
• Probability of regulatory approval success
• Other feasibility considerations (e.g.,
Intellectual Property, manufacturability,
existing data & models)
- Product manufacturing and sales
• Cost of materials
• Sales and distribution, etc.
b. Expected product revenue
i Market predictions - Market size
• Number of farms affected & geographic
distribution
• Disease incidence/prevalence on affected
farms
• Probability of treating affected animals
• Short term economic/animal health impacts
• Long-term impacts on animal productivity





• Global regulatory landscape
• Existing market segmentation
• Predicted market growth
ii Product-
specific predictions
- Expected return on investment (ROI) for
livestock producer/veterinarian
• Animal health & productivity improvements
• Number needed to treat (NNT) to impact
one animal vs. number needed to harm (one
animal, or person in case of public health)
• Other benefits (e.g., enhanced market
access)
- Product competitiveness compared
to substitutes
2. Specific project risks
a. Product safety - Food safety
- Target animal safety
- Microbial safety
- Environmental safety
b. Product efficacy - Effect type and size
- Consistency under real-world conditions




- Product perception/mechanism of action
- Attitudes, beliefs, perceived behavioral
constraints
- Trust in the product’s consistent efficacy
- Product performance relative to expectations
iv Society/consumers - Consumer acceptance
- Ease of explanation
d. Product
practicality/ease of use
- Compatibility with current production
practices
- Administration mode (route, frequency, etc.)
- Associated costs (e.g., labor costs,
withdrawal times)
steps to address it through prevention, control, or treatment.
Economic factors play a role here as well, including short
term disease impacts as well as long-term consequences on
animal health and productivity (10, 11). Mastitis in dairy cattle,
for instance, persistently decreases milk yields in subsequent
lactations (12). Transboundary infectious animal diseases can
also inflict additional economic costs, for instance through trade
restrictions and loss of export markets. In contrast, some animal
diseases are controlled most effectively through culling, and
in certain cases the animal health benefits associated with an
intervention may not outweigh the costs. Given the considerable
R&D costs, to be economically viable, antibiotic alternatives for
food producing species must address relatively common health
problems (i.e., endemic infectious animal diseases) that have
substantial economic and animal health impacts.
Other market characteristics, such as segmentation of the
existing market and predicted market growth, factor into the
revenue calculation as well. In addition, market access may be
greater in more highly integrated industries and for products
with more internationally harmonized regulatory requirements.
Product specific considerations include the expected return
on investment (ROI) for the livestock producer, and the
competitiveness of the product compared to alternatives. As
outlined in Table 1, several factors impact the ROI, making
it potentially challenging to predict (9, 13, 14). Product
competitiveness refers to the availability of “substitutes”—
interventions that address the same health issue. Particular
attention is given to less expensive, easier to administer
or more effective substitutes, which often include existing
antibiotics (5). Expectation of equal or superior performance for
alternatives compared to existing antibiotics may be unrealistic.
However, increasing regulatory and market-based restrictions
on antibiotic use may render even less-effective alternatives
highly competitive. Increasing bacterial resistance to antibiotics
among target pathogens may further reduce the efficacy of
currently available antibiotics (15–17). Currently, few signs point
to this phenomenon as an important driver of demand for
antibiotic alternatives.
Evaluating Project Risks
Even if these initial economic considerations are favorable, an
antibiotic alternative candidate may fail for many reasons.
Product Safety
Product safety (see Table 1) is a prerequisite for the success of
an antibiotic alternative and integral to the regulatory approval
process but may be challenging to predict early in development.
In vitro and in silico models have been developed to help assess
the pharmacokinetics and predict the safety of veterinary drugs
(18). The applicability of these models to antibiotic alternatives
depends on the type of product, and can be influenced by the
mechanism of action, host immune response, and potential for
off-target effects. Ultimately, well-designed in vivo studies are
critical for assuring end-users, regulators, and the public that a
product is safe for animals, humans and the environment.
Product Efficacy
Antibiotic alternatives that do not meet customer expectations
for efficacy in effect type—prevention, control and/or
treatment,—as well as the magnitude and consistency of
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the effect, are unlikely to be successful. The mechanisms by
which alternatives exert their effects are diverse: for instance,
they may enhance host immunity, induce cytotoxic effects in
pathogenic organisms, block proteins that mediate cell entry or
virulence through passive immunization, promote gut health,
exert anti-inflammatory properties, or modulate microbial
communities in the gut (19–27). In general, the magnitude of
the effect is lower for alternatives compared to antibiotics, and
tends to be more variable across settings (5). Clarifying customer
expectations around some minimum threshold for efficacy (for
instance, compared to antibiotics) for the alternative product
candidate may prove useful.
Predicting product efficacy early in R&D can be challenging.
In vitro data are often used to predict efficacy because they are
easier to collect and do not require the larger investments needed
for in vivo studies (28–30). However, predictions based on these
data are less reliable than in vivo studies, which better capture
genetic differences between animals and variations in host-
pathogen interactions and environment. Key design questions
for studies of in vivo efficacy include whether diseases are
experimentally introduced in healthy animals (i.e., challenge
studies) or else the rates of natural disease occurrence are
observed, and whether animals are managed under real world
conditions (i.e., experimental vs. field trials). More tightly-
controlled studies—such as those experimentally infecting a
small number of healthy, genetically homogenous animals
with one pathogen strain at one point in time, can use
smaller experimental group sizes for statistical significance
than less closely controlled studies, but they often do not
adequately capture population-level variations that can impact
efficacy. For instance, the experimental animals may be more
uniform with regard to factors such as age, breed, health
status, management, and disease history than animals in
commercial settings (31). Study complexity and cost also limit
the ability to evaluate efficacy under different animal housing and
management practices.
For many antibiotic alternatives, conclusive data from large,
well-controlled in vivo studies are scarce—an issue that is
compounded by lack of information regarding the products’
mechanism of action (22, 32–34). Potential interactions across
alternatives and efficacy under varying management and
husbandry practices have also remained largely unexplored (5).
In the swine industry, for instance, a range of alternatives have
been studied with mixed results, yet a systematic assessment
of this body of research and a definitive conclusion of overall
impact on swine health remains a major need (35, 36). When
evaluating efficacy, it is important to recognize that many
antibiotic alternatives stimulate host immunity broadly, or else
alter the microbial environment to be less conducive to pathogen
adhesion or propagation, rather than directly kill pathogens or
inhibit their growth.
Product Acceptability
The acceptability of new alternatives by farmers and
veterinarians, who often have vast experience using antibiotics,
is also key to success. Studies have shown that many farmers
and veterinarians are skeptical about the efficacy of antibiotic
alternatives (37–39). Behavioral and socio-economic factors
such as prior experience and risk avoidance clearly impact
decision-making regarding the use of antibiotics or alternatives
(40–42). Behavioral studies related to the use of antibiotics and
other medications in human health care and animal agriculture
have identified attitudes toward the product, belief in its value,
and perceptions of behavioral constraints such as economics,
risk, trust in others, social norms (i.e., expectations of others)
and moral obligation to treat animals under one’s care as core
behavioral drivers (40–43). Building trust in a new product
usually requires, at minimum, evidence of clear and consistent
product efficacy under field conditions. Independent third-party
verification, for instance as part of a data clearing-house or a trial
registry, could help address concerns about data dredging and
cherry-picking of efficacy trials, although it is unlikely to solve all
the underlying challenges and concerns.
The success of an alternative also requires that the animal
products derived using the alternative are acceptable to
consumers. Generally speaking, the biological function of an
alternative should be easy to explain to a layperson and
must align with consumers’ beliefs and expectations concerning
food production and their conceptualizations of risk and
adulteration. Alternatives may be preferable over antibiotics
to some consumers, to the extent that they alleviate concerns
regarding their use (44). In fact, some consumers perceive foods
derived from animals raised without antibiotics as more healthful
or nutritious (45). Ultimately, consumer acceptance of new
technologies is often highly context-specific and affected by a
variety of factors including moral, social, political, economic, and
religious values as well as geographical, ecological, and animal
welfare concerns (46).
Product Practicality and Ease of Use
The widespread adoption of an antibiotic alternative requires that
they be practical to use for farmers and veterinarians. This means
any such product must be integrated into current production
practices without causing major disruptions. Products that
require disruptive shifts in the infrastructure or systems under
which livestock commodities are raised are unlikely to succeed,
at least in the shorter- to medium-term. In addition, products
that are not readily compatible with current animal production
practices—for instance, because of their application frequency,
mode of administration, stability or timing of use—may face
obstacles to adoption. Side-effects of the product or the stress
associated with handling an animal to apply the product may
also reduce adoption. As with antibiotics, farmers may need to
observe specific withdrawal times that may limit their ability to
market animal-derived products.
DISCUSSION
Antibiotic alternatives represent a major unmet need for
the livestock sector. However, the factors predicting their
success or failure are complex. Here, we outline a framework
for the evaluation of alternative candidates that may
empower federal agencies, philanthropic organizations, and
other key stakeholders to consistently and transparently
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prioritize investments in antibiotic alternatives. Our
framework first considers the overall costs and benefits
related to the new alternative, because economic viability
is foundational to ultimate commercial success and this
information may be readily available prior to or early
during R&D.
Ultimately, bringing an alternative to market is an extremely
complex process, involving evaluation of product safety,
efficacy, acceptability and practicality. Therefore, the potential
success of a new alternative may be best evaluated from
multiple perspectives, an approach that we replicated in
our original survey and workshop design and encourage
in the evaluation of alternatives. Research funders may,
for instance, start to involve farmers, veterinarians and
farm advisors more closely in early funding decisions.
Developing new antibiotic alternatives is a challenging
issue but holds considerable promise for animal health and
the fight to combat antibiotic resistance. This framework
will empower research funders to evaluate alternatives early
during R&D, and to dedicate scarce funding to the most
promising alternatives.
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